Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsProperties, production, and applications of camelid single-domain antibody fragmentsTherapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesRibosome-inactivating proteins: from plant defense to tumor attackHuman antibody production in transgenic animalsMoFvAb: Modeling the Fv region of antibodies.Molecular Imaging of Pancreatic Cancer with Antibodies.Affinity maturation of antibodies assisted by in silico modeling.A novel antibody humanization method based on epitopes scanning and molecular dynamics simulationDaclizumab treatment for multiple sclerosis.In vitro antibody affinity maturation targeting germline hotspotsOptimized expression of full-length IgG1 antibody in a common E. coli strain.Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.New directions in nicotine vaccine design and use.Induction of human plasmablasts during infection with antibiotic-resistant nosocomial bacteria.A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategyTargeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody FragmentA recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.Generation and Improvement of Effector Function of a Novel Broadly Reactive and Protective Monoclonal Antibody against Pneumococcal Surface Protein A of Streptococcus pneumoniae.Cloning and sequencing of the light chain variable region from NS-1 myeloma.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Emerging therapies for multiple sclerosis.Therapeutic applications of aptamers.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.Mass spectrometry for the biophysical characterization of therapeutic monoclonal antibodiesMarine Antibody-Drug Conjugates: Design Strategies and Research Progress.Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Acute infusion reactions induced by monoclonal antibody therapy.Nanobody; an old concept and new vehicle for immunotargeting.Dual targeting strategies with bispecific antibodies.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.Antibody-based cancer therapy.The importance of epitope binning for biological drug discovery.Probing binding mechanism of interleukin-6 and olokizumab: in silico design of potential lead antibodies for autoimmune and inflammatory diseases.A snapshot of biologic drug development: Challenges and opportunities.Antibodies as stratagems against cancer.
P2860
Q24289014-3E0E894F-12DD-458E-8AE3-7E15B7174789Q24676749-934D955B-A4F9-472C-8CA1-B32543013006Q26781698-7F402B04-6C35-4336-95E2-F85046BC9DA4Q26828935-65AEB1A5-1AFF-4243-AA9A-AD3561BF5046Q27023477-847100B6-1D69-4A39-B265-7B48B006A894Q30376735-1DF14E2C-F197-4E60-9C04-CEC1E4D0240CQ30393523-B9332E89-164C-4F0A-ABFB-6F4086744641Q30482656-0D9578F0-51ED-485E-B480-A7470DC8A5B6Q31144470-1F5B51D2-5DDF-4411-84F0-E13741274278Q33382919-49F70C3F-0ABD-4A94-8C50-791A12FC1B65Q33413796-3C705620-E853-4194-A162-64BE8C6807E1Q33565621-180B5682-9F90-46F1-8F20-6528588E7298Q33586280-90F76D26-B06D-4407-B33C-0BE95D0CC51EQ33719424-671AE228-4665-4A28-94C9-CCABFF3C66BCQ33746032-B90D1DBD-06E1-49F4-8CCF-0C61819757A2Q33810163-E4593DF1-9D3A-467B-ABAC-7D17269CB530Q34055092-01F430BD-0511-4415-9530-29D7E6697C6FQ35476326-8FE9EC7F-E6C1-4FC4-819A-E99BCBA9389FQ35650818-E7B1FE6F-28C2-4196-9188-BBD6436341F4Q35747230-981EA3FB-9D1C-46EA-A741-C60943166EA5Q36015321-D27D10D0-EEB6-42F5-825A-FA2F76E6FB91Q36076051-F591CC26-983D-44C3-B1FB-574D70C19DC9Q36710927-1D4CE36F-6318-4F2D-9F6D-5CB6A93CE1ECQ36963208-61D69A5E-6279-4BD1-A0DD-D86CD2AAA43FQ37038988-19034B7F-D937-41BA-B62A-2B31D90B85BCQ37174938-10CAB687-0CD5-4BFD-A1E4-831066C22CA8Q37330712-D74FD788-C2C9-439A-8733-0D23C575BE10Q37567087-4CB7A5C9-824E-4036-A05D-3A2F122E3ACAQ37628646-7FC4EFEB-D324-47F3-924E-7426AA089BD5Q37738903-D5778111-19D3-4E7D-B95F-296321DEB27EQ37815479-E0D3F28C-2384-48B9-BE5A-D7F705E2C230Q37821495-4266031B-D810-4020-896B-9C0EB82282E2Q37829737-1A7F7F66-657F-4835-8AB4-8BACA8238BEDQ37997559-1B95A657-F699-4CA6-9D01-AA0AFF00CA86Q37999739-82A4C2AE-1F59-4A4C-9D39-A3D6423EDC47Q38089186-34E52F66-CE0B-4E87-BD63-90339FB3D5A8Q38165212-4F175361-8021-4B78-8D23-CF2DC3726816Q38382090-712876D7-47EE-49EC-ABD7-9CF6A82335E8Q38651271-96B0557C-86B9-489F-B4F0-2C5202F8197FQ38688747-744ACB76-8E87-4F5F-B8A8-41891FB2B2C1
P2860
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@ast
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@en
type
label
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@ast
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@en
prefLabel
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@ast
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@en
P1476
Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.
@en
P2093
Leonard G Presta
P304
P356
10.1016/J.ADDR.2006.01.026
P407
P577
2006-05-23T00:00:00Z